Literature DB >> 31959493

Primary malignant ovarian carcinoid; management and outcomes.

Dimitrios Nasioudis1, Melissa K Frey2, Eloise Chapman-Davis2, Thomas A Caputo2, Kevin Holcomb2.   

Abstract

OBJECTIVE: To investigate the clinicopathological characteristics and survival of patients with malignant ovarian carcinoid tumor (OC).
MATERIALS AND METHODS: The National Cancer Database was accessed and patients diagnosed between 2004 and 2015 with a OC who did not have a personal history of a tumor at another site were selected. Overall survival (OS) was assessed for patients who had ≥1 month of follow-up. OS rates were estimated following generation of Kaplan-Meier curves and compared with the log-rank test.
RESULTS: A total of 588 patients with a median age of 51.5 years were identified. The majority were White (71.6%), had unilateral tumors (94.2%) with a median size of 3.8 cm that were confined to the ovary (88%). Patients with early stage disease (n = 431) had excellent OS compared to those with advanced stage (II-IV) disease (n = 51), p < 0.001; 5-yr OS rates were 95.4% and 53.1% respectively. For patients with stage I disease, there was no difference in OS between those who did (n = 211) and did not (n = 175) have hysterectomy, p = 0.92. For patients with advanced stage disease, administration of adjuvant chemotherapy was not associated with better survival, p = 0.093.
CONCLUSIONS: OCs are typically small, unilateral tumors confined to the ovary arising in perimenopausal patients. Survival outcomes are excellent for patients with early stage disease and unilateral salpingo-oophorectomy appears to be curative.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoid; Hysterectomy; Ovary

Year:  2020        PMID: 31959493     DOI: 10.1016/j.ygyno.2020.01.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  1 in total

1.  Primary neuroendocrine tumors of the ovary: Management and outcomes.

Authors:  Li Pang; Zhiqiang Guo
Journal:  Cancer Med       Date:  2021-11-12       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.